Description:

Size: 100 microliters

Catalog no.: GENTObs-11800R-A594

Price: 489 EUR

Product details

Gene ID

N/A

Swiss Prot

N/A

Modification site

None

Concentration

1ug per 1ul

Excitation emission

590nm/617nm

Subcellular locations

Extracellular

Applications

FCM, IF(IHC-P)

Conjugated

Alexa conjugate 1

Conjugated with

ALEXA FLUOR® 594

Clonality

Polyclonal Antibody

Clone

Polyclonal Antibodies

Purification method

Purified by Protein A.

Target Protein/Peptide

AVPR1B/AVP Receptor V3

Other name

Anti-AVPR1B/AVP Receptor V3

Type

Conjugated Primary Antibody

Conjugation

Alexa Fluor,ALEXA FLUOR® 594

Host organism

Rabbit (Oryctolagus cuniculus)

Also known as

AVPR1B/AVP Receptor V3 Antibody

Applications with corresponding dilutions

FCM(1:20-100), IF(IHC-P)(1:50-200)

Properties

For facs or microscopy Alexa 1 conjugate.

Modification

No modification has been applied to this antibody

Specificity

This antibody reacts specifically with AVPR1B/AVP Receptor V3

Cross reactive species

Human (Homo sapiens), Mouse (Mus musculus), Rat (Rattus norvegicus)

Antigen Source

KLH conjugated synthetic peptide derived from human AVP Receptor V3

Storage

Water buffered solution containing 100ug/ml BSA, 50% glycerol and 0.09% sodium azide. Store at 4°C for 12 months.

Synonyms

Antidiuretic hormone receptor 1b; Arginine vasopressin receptor 1B; Arginine vasopressin receptor 3; AVPR V1b; AVPR V3; Avpr1b; AVPR3; Pituitary vasopressin receptor 3; V1bR; V1BR_HUMAN; Vasopressin V1b receptor; Vasopressin V3 receptor; VPR3.

Cross Reactive Species details

No significant cross reactivity has been observed for this antibody for the tested species. However, note that due to limited knowledge it is impossible to predict with 100% guarantee that the antibody does not corss react with any other species.

Advisory

Avoid freeze/thaw cycles as they may denaturate the polypeptide chains of the antibody, thus reducing its reactivity, specificity and sensitivity. For antibodies that are in liquid form or reconstituted lyophilized antibodies small amounts could become entrapped on the seal or the walls of the tube. Prior to use briefly centrifuge the vial to gather all the solution on the bottom.

Description

This antibody needs to be stored at + 4°C in a fridge short term in a concentrated dilution. Freeze thaw will destroy a percentage in every cycle and should be avoided.The receptors are ligand binding factors of type 1, 2 or 3 and protein-molecules that receive chemical-signals from outside a cell. When such chemical-signals couple or bind to a receptor, they cause some form of cellular/tissue-response, e.g. a change in the electrical-activity of a cell. In this sense, am olfactory receptor is a protein-molecule that recognizes and responds to endogenous-chemical signals, chemokinesor cytokines e.g. an acetylcholine-receptor recognizes and responds to its endogenous-ligand, acetylcholine. However, sometimes in pharmacology, the term is also used to include other proteins that are drug-targets, such as enzymes, transporters and ion-channels.

Background information

Vasopressin (AVP), the antidiuretic hormone, is a cyclic nonpeptide that is involved in the regulation of body fluid osmolality (1-3). AVP mediates its effects through a family of G-protein coupled receptors, the vasopressin receptors type V1a, V2 and V3 (also designated V1b) (1,2). The AVP receptor V1a is responsible for several functions, including blood vessel constriction, liver glycogenolysis and platelet adhesion (3). It is detected as a full length protein and a shorter protein, which results from proteolytic cleavage of its amino terminus (4). The V1a receptor is coupled to Gq/11 protein, which increases the intracellular calcium concentration (3). The human AVP receptor V2 gene maps to chromosome Xq28 and is expressed in lung and kidney (5,6). Mutations in the V2 receptor result in nephrogenic diabetes insipidus (NDI), a rare X-linked disorder characterized by the inability of the kidney to concentrate urine in response to AVP (5,7). The AVP Receptor V2 activates the Gs protein and the cyclic AMP second messenger system (7). The AVP receptor V3 is preferentially expressed in the pituitary and stimulates the release of adrenocorticotropic hormone (ACTH) in response to AVP by mobilizing intracellular calcium stores (8). AVP receptor antagonists may have potential therapeutic effects in hypertension, congestive heart failure, nephrotic syndrome and ACTH-secreting tumors (2).